The mission of Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) is to identify, prioritize, coordinate, and sponsor innovative activities that will expedite the identification and development of efficacious and safe analgesic, anesthetic, and addiction therapeutic interventions for the benefit of the public health.

ACTTION is designed to optimize the quality and informativeness of the research methods used for evaluating novel preventive, disease-modifying, and symptomatic treatments. The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including academia, national and international government agencies, industry, professional societies, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing innovative thinking and data. These strategic collaborations involve a broad range of activities, for example, systematic reviews and meta-analyses, evidence-based consensus meetings, and preclinical and clinical studies. ACTTION receives grants, contracts, and other funds from the U.S. Food and Drug Administration (FDA), industry, philanthropy, and royalties, and an ongoing FDA cooperative agreement provides support for the ACTTION/PASI (Pediatric Anesthesia Safety Initiative) public-private partnership with the FDA.

ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.

News

February 27, 2024: Second ABC Presentation

Kelley Kidwell, PhD, Professor of Biostatistics, University of Michigan, delivered the second presentation for the ACTTION Biostatistics Charrette (ABC). A recording of her presentation, “Study Design Considerations for Rare Phenotypes/Diseases,” is found here.

November, 2023: ACTTION Reaches Milestone of 175 Publications

September, 2022: ACTTION Awarded New FDA Grant

ACTTION has been awarded a cooperative agreement for 9/2022-8/2027 that expands its activities to address FDA’s Pediatric Anesthesia Safety Initiative.

September, 2021: ACTTION Guide to Clinical Trials of Pain Treatments

The ACTTION Guide to Clinical Trials of Pain Treatments consists of two supplements in Pain Reports. Part I includes 9 articles found here, and Part II includes 6 articles found here.